Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
CVC Technologies Inc. (4744.TWO)
Taichung, TW
CVC Technologies Inc. is a global supplier specializing in the production and distribution of a comprehensive array of pharmaceutical packaging machinery. Their extensive product portfolio addresses diverse packaging needs, featuring advanced tablet counting systems such as bottle unscramblers, air rinsers, tablet and capsule counters/fillers, desiccant and cotton/foam inserters, and a variety of cappers (including chuck, rotary, vial, in-line, and vibratory press models). Other offerings in this category include induction cap sealers, shrink bundlers and tunnels, intermittent cartoners, and sophisticated track and trace machines. The company also provides a wide selection of labeling equipment, like top/bottom/side, wrap-around, and front/back labelers, alongside leaflet topserters, shrink sleeve applicators, and specialized labeler inspection systems. For liquid and powder applications, CVC offers integrated solutions, encompassing bottle unscramblers and air rinsers, liquid fillers and cappers, dedicated capping machines, induction capsealers, labeling units, and cartoner/shrink systems. Further product offerings extend to encapsulation machines, aluminum foil sealing devices, and semi-automatic tablet/capsule counters. Auxiliary equipment is also available, comprising items like jet masters, capsule printing machines, paste making systems, gelatin melting tanks, medicine preparation and drying systems, gelatin reclaim systems, and capsule inspection machines. Beyond its machinery, CVC Technologies Inc. delivers a full suite of support services. These include expert packaging line design, factory acceptance testing, technical phone assistance, field service and preventative maintenance, as well as installation, startup, and training programs. Established in 1979, the company is based in Taichung, Taiwan.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.44% | +3.28% | +4.69% | +7.79% | +11.79% | +19.52% | +63.59% | -12.96% | +35.37% | +33.85% | -59.71% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2025-12 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Industrial - Machinery: +7.4%+12.2% ★ Q1'26: -14.7% (vs Q1'25)
-
EPS growth Industrial - Machinery: +15.6%+236.5% ★ Q1'26: -139.3% (vs Q1'25)
-
FCF margin FCF growth · Industrial - Machinery: +38.2%-1.1% Q1'26: +27.6% (vs Q1'25)
-
EBIT margin Industrial - Machinery: +10.0%+12.9% ★ Q1'26: -8.8% (vs Q1'25)
-
ROIC Industrial - Machinery: +6.8%+11.8% ★ Q1'26: -5.2% (vs Q1'25)
-
Share dilution Industrial - Machinery: +0.0%-4.9% ★ Q1'26: +1.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Industrial - Machinery: -0.65×2.11× Q1'26: -10.55× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2022 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|
| Revenue |
902.83M
est: 1.20B (-24.6%)
|
1.44B
est: 1.56B (-7.4%)
|
1.88B
1.88B – 1.88B
+20.2% YoY
|
| EBITDA |
113.59M
est: 123.79M (-8.2%)
|
230.32M
est: 175.78M (+31.0%)
|
211.27M
211.27M – 211.27M
+20.2% YoY
|
| EBIT |
92.61M
est: 92.48M (+0.1%)
|
186.75M
est: 132.16M (+41.3%)
|
158.84M
158.84M – 158.84M
+20.2% YoY
|
| Net Income |
56.26M
|
134.99M
est: 115.82M (+16.6%)
|
168.31M
168.31M – 168.31M
+45.3% YoY
|
| SGA |
346.52M
est: 412.78M (-16.1%)
|
436.62M
est: 540.48M (-19.2%)
|
649.61M
649.61M – 649.61M
+20.2% YoY
|
| EPS |
1.24
|
2.49
est: 2.14 (+16.4%)
|
3.11
3.11 – 3.11
+45.3% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-28 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-27 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-26 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-25 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-22 | A- | 4/5 | 5/5 | 3/5 | 4/5 | 2/5 | 3/5 | 3/5 |
| 2026-05-21 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-20 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-19 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-18 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-15 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-05-14 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-05-13 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-05-12 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-05-11 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-05-08 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-05-07 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-05-06 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-05-05 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-05-04 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-30 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-29 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-28 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-27 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-24 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 4/5 | 4/5 |
| 2026-04-23 | A | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-22 | A | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-21 | A | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-20 | A | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-17 | A | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 4/5 | 4/5 |
| 2026-04-16 | A | 4/5 | 5/5 | 3/5 | 5/5 | 1/5 | 4/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Chin-Chia Chang | Financial Supervisor & Corporate Governance Officer | — | — |
| Hannong Chen | Accounting Supervisor | — | — |
| Jing-Yi Lin | Executive Vice President & Chairperson | — | female |
| Li-Feng Lin | Senior Sales Manager & Representative Supervisor | — | — |
| Shi Hao Yang | Sales General Manager and Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4744.TWO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
